Subcutaneous Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis.

Achille Marino, Luca Marelli, Paolo Nucci, Roberto Caporali, Elisabetta Miserocchi

Ocular immunology and inflammation 2023 Dec

filter terms:

To describe the efficacy and safety of subcutaneous tocilizumab (SC-TCZ) in a cohort of juvenile idiopathic arthritis (JIA) patients with refractory uveitis. Retrospective observational monocentric study including patients with JIA-associated uveitis treated with SC-TCZ. Thirteen patients were enrolled. The rate of uveitis flare/year per each patient was 1.6 ± 2.0 on the last bDMARDs before SC-TCZ, while it decreased to 0.4 ± 0.7 on SC-TCZ. Nine out of thirteen patients (69%) required the introduction of SC-TCZ only for active uveitis at baseline. Among these patients, five (56%) achieved complete treatment response. No uveitis relapses were observed in patients (4/13, 31%) requiring the introduction of SC-TCZ for active arthritis during follow-up (30.48 ± 21.6 months). Overall, SC-TCZ was safe, and no side effects were observed during the treatment. SC-TCZ can be effective and safe in patients with JIA and uveitis recalcitrant to several bDMARDs.

Citation

Achille Marino, Luca Marelli, Paolo Nucci, Roberto Caporali, Elisabetta Miserocchi. Subcutaneous Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis. Ocular immunology and inflammation. 2023 Dec;31(10):1997-2000